Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
8.93
+0.38 (4.44%)
At close: Aug 21, 2026, 4:00 PM EDT
8.51
-0.42 (-4.70%)
Pre-market: Aug 24, 2026, 7:44 AM EDT
Immatics Employees
Immatics had 678 employees as of March 31, 2026. The number of employees decreased by 33 or -4.64% since the number was last reported on December 31, 2025.
Employees
678
Change
-33
Growth
-4.64%
Revenue / Employee
$70,273
Profits / Employee
-$348,046
Market Cap
1.22B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 678 | -33 | -4.64% | 678 | 0 |
| Dec 31, 2025 | 711 | 29 | 4.25% | 589 | 122 |
| Dec 31, 2024 | 682 | 147 | 27.48% | 554 | 128 |
| Dec 31, 2023 | 535 | 93 | 21.04% | 432 | 103 |
| Dec 31, 2022 | 442 | 61 | 16.01% | 358 | 84 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| Monte Rosa Therapeutics | 173 |
| Sana Biotechnology | 142 |
| MoonLake Immunotherapeutics | 130 |
| Odyssey Therapeutics | 100 |
| Inventiva | 77 |
| Alto Neuroscience | 68 |
| Seaport Therapeutics | 58 |
IMTX News
- 6 days ago - Immatics reports Q2 EPS (46c), consensus (48c) - TheFly
- 6 days ago - Immatics Announces Second Quarter 2026 Financial Results and Business Update - GlobeNewsWire
- 5 weeks ago - Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 - GlobeNewsWire
- 3 months ago - Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - Immatics announces presentation of extended data from Phase 1 trial of IMA401 - TheFly
- 3 months ago - Immatics announces updated Phase 1 data for its Prame TCR T-cell therapy - TheFly
- 3 months ago - Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer - GlobeNewsWire
- 3 months ago - Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting - GlobeNewsWire